ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LAB vs PACB // EV/EBITDA & P/E VALUATION

Standard BioTools Inc. (NASDAQ) VS. Pacific Biosciences of California Inc. (NASDAQ) • 15-METRIC TALLY: LAB 3 — PACB 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LAB VS. PACB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LAB PACB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 49.90% 28.60% +21.30 LAB /gross-margins <GO>
Return on Invested Capital (ROIC) -28.70% -35.00% +6.30 LAB /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — -12.64% — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -6.20% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 LAB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.8 61.4 -23.61 PACB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $244.7M $901.4M -$656.7M PACB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LAB REV PACB REV LAB GROSS % PACB GROSS % LAB FCF PACB FCF
FY 2025 $85.3M $160.0M 49.9% 28.6% -$82.6M -$113.9M
FY 2024 $91.0M $154.0M 49.3% 24.2% -$151.8M -$212.2M
FY 2023 $106.3M $0 — — -$43.3M -$259.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LAB // BETA —
PACB // BETA —